カテゴリ： 世界, 医療/バイオ, Market Monitor Global

バイオ医薬品CDMOのグローバル市場展望 2023年-2029年：開発＆製造CDMO、治験材料CDMO、フィルフィニッシュCDMO、その他

■ 英語タイトル：Biopharmaceutical CDMO Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12269）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12269
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：105
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[バイオ医薬品CDMOのグローバル市場展望 2023年-2029年：開発＆製造CDMO、治験材料CDMO、フィルフィニッシュCDMO、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のバイオ医薬品CDMO市場規模と予測を収録しています。・世界のバイオ医薬品CDMO市場：売上、2018年-2023年、2024年-2029年
・世界のバイオ医薬品CDMO市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のバイオ医薬品CDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「開発＆製造CDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

バイオ医薬品CDMOのグローバル主要企業は、Lonza、 WuXi AppTec、 Catalent、 Thermo Fisher、 Recipharm、 Samsung Biologics、 Siegfried、 Delpharm、 Boehringer Ingelheim、 Aenova Group、 AGC Parma Chemicals、 GenScript、 ProBioGen、 KBI Biopharma、 3P Biopharmaceuticals、 Rentschler Biopharma、 Northway Biotechなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、バイオ医薬品CDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のバイオ医薬品CDMO市場：タイプ別、2018年-2023年、2024年-2029年
世界のバイオ医薬品CDMO市場：タイプ別市場シェア、2022年
・開発＆製造CDMO、治験材料CDMO、フィルフィニッシュCDMO、その他

世界のバイオ医薬品CDMO市場：用途別、2018年-2023年、2024年-2029年
世界のバイオ医薬品CDMO市場：用途別市場シェア、2022年
・製薬会社、バイオテクノロジー会社、その他

世界のバイオ医薬品CDMO市場：地域・国別、2018年-2023年、2024年-2029年
世界のバイオ医薬品CDMO市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるバイオ医薬品CDMOのグローバル売上、2018年-2023年
・主要企業におけるバイオ医薬品CDMOのグローバル売上シェア、2022年
・主要企業におけるバイオ医薬品CDMOのグローバル販売量、2018年-2023年
・主要企業におけるバイオ医薬品CDMOのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Lonza、 WuXi AppTec、 Catalent、 Thermo Fisher、 Recipharm、 Samsung Biologics、 Siegfried、 Delpharm、 Boehringer Ingelheim、 Aenova Group、 AGC Parma Chemicals、 GenScript、 ProBioGen、 KBI Biopharma、 3P Biopharmaceuticals、 Rentschler Biopharma、 Northway Biotech

*************************************************************

・調査・分析レポートの概要
バイオ医薬品CDMO市場の定義
市場セグメント
世界のバイオ医薬品CDMO市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のバイオ医薬品CDMO市場規模
世界のバイオ医薬品CDMO市場規模：2022年 VS 2029年
世界のバイオ医薬品CDMO市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのバイオ医薬品CDMOの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のバイオ医薬品CDMO製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：開発＆製造CDMO、治験材料CDMO、フィルフィニッシュCDMO、その他
バイオ医薬品CDMOのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：製薬会社、バイオテクノロジー会社、その他
バイオ医薬品CDMOの用途別グローバル売上・予測

・地域別市場分析
地域別バイオ医薬品CDMO市場規模 2022年と2029年
地域別バイオ医薬品CDMO売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Lonza、 WuXi AppTec、 Catalent、 Thermo Fisher、 Recipharm、 Samsung Biologics、 Siegfried、 Delpharm、 Boehringer Ingelheim、 Aenova Group、 AGC Parma Chemicals、 GenScript、 ProBioGen、 KBI Biopharma、 3P Biopharmaceuticals、 Rentschler Biopharma、 Northway Biotech
...

This research report provides a comprehensive analysis of the Biopharmaceutical CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Biopharmaceutical CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Biopharmaceutical CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Biopharmaceutical CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Biopharmaceutical CDMO market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Biopharmaceutical CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Biopharmaceutical CDMO market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Biopharmaceutical CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Biopharmaceutical CDMO market.
Market Overview: The report provides a comprehensive overview of the Biopharmaceutical CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Development and Manufacturing CDMOs, Clinical Trial Material CDMOs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Biopharmaceutical CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Biopharmaceutical CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Biopharmaceutical CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Biopharmaceutical CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Biopharmaceutical CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Biopharmaceutical CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Biopharmaceutical CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Biopharmaceutical CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Biopharmaceutical CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Development and Manufacturing CDMOs
Clinical Trial Material CDMOs
Fill-Finish CDMOs
Other
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Global Biopharmaceutical CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Lonza
WuXi AppTec
Catalent
Thermo Fisher
Recipharm
Samsung Biologics
Siegfried
Delpharm
Boehringer Ingelheim
Aenova Group
AGC Parma Chemicals
GenScript
ProBioGen
KBI Biopharma
3P Biopharmaceuticals
Rentschler Biopharma
Northway Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biopharmaceutical CDMO, market overview.
Chapter 2: Global Biopharmaceutical CDMO market size in revenue.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biopharmaceutical CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Biopharmaceutical CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biopharmaceutical CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biopharmaceutical CDMO Overall Market Size
2.1 Global Biopharmaceutical CDMO Market Size: 2022 VS 2029
2.2 Global Biopharmaceutical CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Biopharmaceutical CDMO Players in Global Market
3.2 Top Global Biopharmaceutical CDMO Companies Ranked by Revenue
3.3 Global Biopharmaceutical CDMO Revenue by Companies
3.4 Top 3 and Top 5 Biopharmaceutical CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Biopharmaceutical CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Biopharmaceutical CDMO Players in Global Market
3.6.1 List of Global Tier 1 Biopharmaceutical CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Biopharmaceutical CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Biopharmaceutical CDMO Market Size Markets, 2022 & 2029
4.1.2 Development and Manufacturing CDMOs
4.1.3 Clinical Trial Material CDMOs
4.1.4 Fill-Finish CDMOs
4.1.5 Other
4.2 By Type – Global Biopharmaceutical CDMO Revenue & Forecasts
4.2.1 By Type – Global Biopharmaceutical CDMO Revenue, 2018-2023
4.2.2 By Type – Global Biopharmaceutical CDMO Revenue, 2024-2029
4.2.3 By Type – Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Biopharmaceutical CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Other
5.2 By Application – Global Biopharmaceutical CDMO Revenue & Forecasts
5.2.1 By Application – Global Biopharmaceutical CDMO Revenue, 2018-2023
5.2.2 By Application – Global Biopharmaceutical CDMO Revenue, 2024-2029
5.2.3 By Application – Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Biopharmaceutical CDMO Market Size, 2022 & 2029
6.2 By Region – Global Biopharmaceutical CDMO Revenue & Forecasts
6.2.1 By Region – Global Biopharmaceutical CDMO Revenue, 2018-2023
6.2.2 By Region – Global Biopharmaceutical CDMO Revenue, 2024-2029
6.2.3 By Region – Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Biopharmaceutical CDMO Revenue, 2018-2029
6.3.2 US Biopharmaceutical CDMO Market Size, 2018-2029
6.3.3 Canada Biopharmaceutical CDMO Market Size, 2018-2029
6.3.4 Mexico Biopharmaceutical CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Biopharmaceutical CDMO Revenue, 2018-2029
6.4.2 Germany Biopharmaceutical CDMO Market Size, 2018-2029
6.4.3 France Biopharmaceutical CDMO Market Size, 2018-2029
6.4.4 U.K. Biopharmaceutical CDMO Market Size, 2018-2029
6.4.5 Italy Biopharmaceutical CDMO Market Size, 2018-2029
6.4.6 Russia Biopharmaceutical CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Biopharmaceutical CDMO Market Size, 2018-2029
6.4.8 Benelux Biopharmaceutical CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Biopharmaceutical CDMO Revenue, 2018-2029
6.5.2 China Biopharmaceutical CDMO Market Size, 2018-2029
6.5.3 Japan Biopharmaceutical CDMO Market Size, 2018-2029
6.5.4 South Korea Biopharmaceutical CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Biopharmaceutical CDMO Market Size, 2018-2029
6.5.6 India Biopharmaceutical CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Biopharmaceutical CDMO Revenue, 2018-2029
6.6.2 Brazil Biopharmaceutical CDMO Market Size, 2018-2029
6.6.3 Argentina Biopharmaceutical CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Biopharmaceutical CDMO Revenue, 2018-2029
6.7.2 Turkey Biopharmaceutical CDMO Market Size, 2018-2029
6.7.3 Israel Biopharmaceutical CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Biopharmaceutical CDMO Market Size, 2018-2029
6.7.5 UAE Biopharmaceutical CDMO Market Size, 2018-2029
7 Biopharmaceutical CDMO Companies Profiles
7.1 Lonza
7.1.1 Lonza Company Summary
7.1.2 Lonza Business Overview
7.1.3 Lonza Biopharmaceutical CDMO Major Product Offerings
7.1.4 Lonza Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.1.5 Lonza Key News & Latest Developments
7.2 WuXi AppTec
7.2.1 WuXi AppTec Company Summary
7.2.2 WuXi AppTec Business Overview
7.2.3 WuXi AppTec Biopharmaceutical CDMO Major Product Offerings
7.2.4 WuXi AppTec Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.2.5 WuXi AppTec Key News & Latest Developments
7.3 Catalent
7.3.1 Catalent Company Summary
7.3.2 Catalent Business Overview
7.3.3 Catalent Biopharmaceutical CDMO Major Product Offerings
7.3.4 Catalent Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.3.5 Catalent Key News & Latest Developments
7.4 Thermo Fisher
7.4.1 Thermo Fisher Company Summary
7.4.2 Thermo Fisher Business Overview
7.4.3 Thermo Fisher Biopharmaceutical CDMO Major Product Offerings
7.4.4 Thermo Fisher Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.4.5 Thermo Fisher Key News & Latest Developments
7.5 Recipharm
7.5.1 Recipharm Company Summary
7.5.2 Recipharm Business Overview
7.5.3 Recipharm Biopharmaceutical CDMO Major Product Offerings
7.5.4 Recipharm Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.5.5 Recipharm Key News & Latest Developments
7.6 Samsung Biologics
7.6.1 Samsung Biologics Company Summary
7.6.2 Samsung Biologics Business Overview
7.6.3 Samsung Biologics Biopharmaceutical CDMO Major Product Offerings
7.6.4 Samsung Biologics Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.6.5 Samsung Biologics Key News & Latest Developments
7.7 Siegfried
7.7.1 Siegfried Company Summary
7.7.2 Siegfried Business Overview
7.7.3 Siegfried Biopharmaceutical CDMO Major Product Offerings
7.7.4 Siegfried Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.7.5 Siegfried Key News & Latest Developments
7.8 Delpharm
7.8.1 Delpharm Company Summary
7.8.2 Delpharm Business Overview
7.8.3 Delpharm Biopharmaceutical CDMO Major Product Offerings
7.8.4 Delpharm Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.8.5 Delpharm Key News & Latest Developments
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Company Summary
7.9.2 Boehringer Ingelheim Business Overview
7.9.3 Boehringer Ingelheim Biopharmaceutical CDMO Major Product Offerings
7.9.4 Boehringer Ingelheim Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.9.5 Boehringer Ingelheim Key News & Latest Developments
7.10 Aenova Group
7.10.1 Aenova Group Company Summary
7.10.2 Aenova Group Business Overview
7.10.3 Aenova Group Biopharmaceutical CDMO Major Product Offerings
7.10.4 Aenova Group Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.10.5 Aenova Group Key News & Latest Developments
7.11 AGC Parma Chemicals
7.11.1 AGC Parma Chemicals Company Summary
7.11.2 AGC Parma Chemicals Business Overview
7.11.3 AGC Parma Chemicals Biopharmaceutical CDMO Major Product Offerings
7.11.4 AGC Parma Chemicals Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.11.5 AGC Parma Chemicals Key News & Latest Developments
7.12 GenScript
7.12.1 GenScript Company Summary
7.12.2 GenScript Business Overview
7.12.3 GenScript Biopharmaceutical CDMO Major Product Offerings
7.12.4 GenScript Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.12.5 GenScript Key News & Latest Developments
7.13 ProBioGen
7.13.1 ProBioGen Company Summary
7.13.2 ProBioGen Business Overview
7.13.3 ProBioGen Biopharmaceutical CDMO Major Product Offerings
7.13.4 ProBioGen Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.13.5 ProBioGen Key News & Latest Developments
7.14 KBI Biopharma
7.14.1 KBI Biopharma Company Summary
7.14.2 KBI Biopharma Business Overview
7.14.3 KBI Biopharma Biopharmaceutical CDMO Major Product Offerings
7.14.4 KBI Biopharma Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.14.5 KBI Biopharma Key News & Latest Developments
7.15 3P Biopharmaceuticals
7.15.1 3P Biopharmaceuticals Company Summary
7.15.2 3P Biopharmaceuticals Business Overview
7.15.3 3P Biopharmaceuticals Biopharmaceutical CDMO Major Product Offerings
7.15.4 3P Biopharmaceuticals Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.15.5 3P Biopharmaceuticals Key News & Latest Developments
7.16 Rentschler Biopharma
7.16.1 Rentschler Biopharma Company Summary
7.16.2 Rentschler Biopharma Business Overview
7.16.3 Rentschler Biopharma Biopharmaceutical CDMO Major Product Offerings
7.16.4 Rentschler Biopharma Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.16.5 Rentschler Biopharma Key News & Latest Developments
7.17 Northway Biotech
7.17.1 Northway Biotech Company Summary
7.17.2 Northway Biotech Business Overview
7.17.3 Northway Biotech Biopharmaceutical CDMO Major Product Offerings
7.17.4 Northway Biotech Biopharmaceutical CDMO Revenue in Global Market (2018-2023)
7.17.5 Northway Biotech Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Biopharmaceutical CDMO Market Opportunities & Trends in Global Market
Table 2. Biopharmaceutical CDMO Market Drivers in Global Market
Table 3. Biopharmaceutical CDMO Market Restraints in Global Market
Table 4. Key Players of Biopharmaceutical CDMO in Global Market
Table 5. Top Biopharmaceutical CDMO Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Biopharmaceutical CDMO Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Biopharmaceutical CDMO Revenue Share by Companies, 2018-2023
Table 8. Global Companies Biopharmaceutical CDMO Product Type
Table 9. List of Global Tier 1 Biopharmaceutical CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Biopharmaceutical CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Biopharmaceutical CDMO Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Biopharmaceutical CDMO Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Biopharmaceutical CDMO Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Biopharmaceutical CDMO Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Biopharmaceutical CDMO Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Biopharmaceutical CDMO Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Biopharmaceutical CDMO Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Biopharmaceutical CDMO Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Biopharmaceutical CDMO Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Biopharmaceutical CDMO Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Biopharmaceutical CDMO Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Biopharmaceutical CDMO Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Biopharmaceutical CDMO Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Biopharmaceutical CDMO Revenue, (US$, Mn), 2024-2029
Table 30. Lonza Company Summary
Table 31. Lonza Biopharmaceutical CDMO Product Offerings
Table 32. Lonza Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 33. Lonza Key News & Latest Developments
Table 34. WuXi AppTec Company Summary
Table 35. WuXi AppTec Biopharmaceutical CDMO Product Offerings
Table 36. WuXi AppTec Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 37. WuXi AppTec Key News & Latest Developments
Table 38. Catalent Company Summary
Table 39. Catalent Biopharmaceutical CDMO Product Offerings
Table 40. Catalent Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 41. Catalent Key News & Latest Developments
Table 42. Thermo Fisher Company Summary
Table 43. Thermo Fisher Biopharmaceutical CDMO Product Offerings
Table 44. Thermo Fisher Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 45. Thermo Fisher Key News & Latest Developments
Table 46. Recipharm Company Summary
Table 47. Recipharm Biopharmaceutical CDMO Product Offerings
Table 48. Recipharm Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 49. Recipharm Key News & Latest Developments
Table 50. Samsung Biologics Company Summary
Table 51. Samsung Biologics Biopharmaceutical CDMO Product Offerings
Table 52. Samsung Biologics Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 53. Samsung Biologics Key News & Latest Developments
Table 54. Siegfried Company Summary
Table 55. Siegfried Biopharmaceutical CDMO Product Offerings
Table 56. Siegfried Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 57. Siegfried Key News & Latest Developments
Table 58. Delpharm Company Summary
Table 59. Delpharm Biopharmaceutical CDMO Product Offerings
Table 60. Delpharm Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 61. Delpharm Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Biopharmaceutical CDMO Product Offerings
Table 64. Boehringer Ingelheim Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. Aenova Group Company Summary
Table 67. Aenova Group Biopharmaceutical CDMO Product Offerings
Table 68. Aenova Group Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 69. Aenova Group Key News & Latest Developments
Table 70. AGC Parma Chemicals Company Summary
Table 71. AGC Parma Chemicals Biopharmaceutical CDMO Product Offerings
Table 72. AGC Parma Chemicals Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 73. AGC Parma Chemicals Key News & Latest Developments
Table 74. GenScript Company Summary
Table 75. GenScript Biopharmaceutical CDMO Product Offerings
Table 76. GenScript Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 77. GenScript Key News & Latest Developments
Table 78. ProBioGen Company Summary
Table 79. ProBioGen Biopharmaceutical CDMO Product Offerings
Table 80. ProBioGen Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 81. ProBioGen Key News & Latest Developments
Table 82. KBI Biopharma Company Summary
Table 83. KBI Biopharma Biopharmaceutical CDMO Product Offerings
Table 84. KBI Biopharma Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 85. KBI Biopharma Key News & Latest Developments
Table 86. 3P Biopharmaceuticals Company Summary
Table 87. 3P Biopharmaceuticals Biopharmaceutical CDMO Product Offerings
Table 88. 3P Biopharmaceuticals Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 89. 3P Biopharmaceuticals Key News & Latest Developments
Table 90. Rentschler Biopharma Company Summary
Table 91. Rentschler Biopharma Biopharmaceutical CDMO Product Offerings
Table 92. Rentschler Biopharma Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 93. Rentschler Biopharma Key News & Latest Developments
Table 94. Northway Biotech Company Summary
Table 95. Northway Biotech Biopharmaceutical CDMO Product Offerings
Table 96. Northway Biotech Biopharmaceutical CDMO Revenue (US$, Mn) & (2018-2023)
Table 97. Northway Biotech Key News & Latest Developments
List of Figures
Figure 1. Biopharmaceutical CDMO Segment by Type in 2022
Figure 2. Biopharmaceutical CDMO Segment by Application in 2022
Figure 3. Global Biopharmaceutical CDMO Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Biopharmaceutical CDMO Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Biopharmaceutical CDMO Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2022
Figure 8. By Type - Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 9. By Application - Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 10. By Type - Global Biopharmaceutical CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 12. By Application - Global Biopharmaceutical CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 14. By Region - Global Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 15. By Country - North America Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 16. US Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 20. Germany Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 21. France Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 28. China Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 32. India Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 34. Brazil Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Biopharmaceutical CDMO Revenue Market Share, 2018-2029
Figure 37. Turkey Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Biopharmaceutical CDMO Revenue, (US$, Mn), 2018-2029
Figure 41. Lonza Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. WuXi AppTec Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Catalent Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Thermo Fisher Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Recipharm Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Samsung Biologics Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Siegfried Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Delpharm Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Boehringer Ingelheim Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Aenova Group Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. AGC Parma Chemicals Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. GenScript Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. ProBioGen Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. KBI Biopharma Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. 3P Biopharmaceuticals Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Rentschler Biopharma Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Northway Biotech Biopharmaceutical CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ジェネリック医薬品中間体CDMOサービスのグローバル市場展望 2023年-2029年：中間体プロセス最適化、中間体製造
  • 製剤CDMOサービスのグローバル市場展望 2023年-2029年：低分子CDMO、高分子CDMO
  • 細胞&遺伝子治療CDMOのグローバル市場展望 2023年-2029年：治験材料用CDMO、開発&製造用CDMO、その他
  • 化学CDMOのグローバル市場展望 2023年-2029年：低分子製剤、高分子製剤
  • ヘパリンのグローバル市場展望 2023年-2029年：ナトリウム、カルシウム
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12269 )"バイオ医薬品CDMOのグローバル市場展望 2023年-2029年：開発＆製造CDMO、治験材料CDMO、フィルフィニッシュCDMO、その他" (英文：Biopharmaceutical CDMO Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。